HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Heartburn Remedy Options Remain Robust Without Ranitidine

Executive Summary

FDA advising consumers to choose other heartburn OTCs but isn't ordering ranitidine off market. Consumers concerned about Johnson's Baby Powder due to potential asbestos can choose not only from other brands, but also from Johnson's in containers other than 22-ounce option on recall.

You may also be interested in...



Direct Seller's CBD Supplement Recall Mandated, More Ranitidine, Tween Cosmetic Recalls

FDA's latest recalls records update includes Basic Reset CBD supplements and another 4,300 units of Tween Brands cosmetics containing colors made from banned dye. Recalls resulting from testing of ranitidine drugs reported by Dr. Reddy's.

OTC Zantac Recall: Sanofi Heeds To Potential Ranitidine Contaminant

Firm opts for recall "as a precautionary measure due to inconsistencies in preliminary test results of the active ingredient used in the US and Canadian products." Other firms marketing ranitidine in US have started recalls due to concerns about NDMA since potential problem became known in September.

J&J Starts First Baby Powder Recall Linked To Asbestos Finding

Recall announcement doesn't mention litigation J&JU faces in multiple states alleging use of Johnson's Baby Powder causes cancer due from talc in formulation. But firm's sensitivity to consumer complaints or adverse event reports linked to brand is clear with talc-related litigation as backdrop.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149348

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel